How Does Wegovy Work in the Body: The Complete Mechanism from Injection Site to Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's active ingredient, semaglutide, mimics the natural hormone GLP-1, binding to receptors in the brain's appetite centers, pancreas, and stomach to reduce hunger and slow digestion
• The medication reaches peak blood concentration 1 to 3 days after injection and maintains therapeutic levels for 7 days due to albumin binding that prevents rapid breakdown
• Weight loss occurs through three simultaneous pathways: reduced appetite via hypothalamic GLP-1 receptors, delayed gastric emptying that extends fullness, and improved insulin response that stabilizes blood sugar
• The brain mechanism is specific: semaglutide activates POMC neurons in the arcuate nucleus while inhibiting AgRP neurons, the same circuits that regulate natural satiety after eating

Direct answer (40-60 words)

Wegovy (semaglutide) works by mimicking GLP-1, a natural gut hormone that signals fullness. After subcutaneous injection, semaglutide binds to albumin in the bloodstream, allowing gradual release over seven days. It activates GLP-1 receptors in the brain's appetite centers, pancreas, and stomach, reducing hunger, slowing digestion, and improving blood sugar control simultaneously.

Table of contents

1. The 60-second mechanism overview
2. What happens in the first hour after injection
3. The albumin-binding trick that makes weekly dosing possible
4. The three-pathway model: brain, stomach, pancreas
5. The brain mechanism: which neurons semaglutide activates
6. Why gastric emptying matters more than most articles explain
7. The pancreatic effect: insulin and glucagon changes
8. What most articles get wrong about GLP-1 receptor distribution
9. The dose-response relationship: why 2.4 mg works differently than 0.25 mg
10. Timeline: when each mechanism reaches full effect
11. Why compounded semaglutide works through identical pathways
12. When the mechanism fails: the 10-15% non-responder pattern
13. FAQ
14. Sources

The 60-second mechanism overview

Wegovy contains semaglutide, a synthetic version of glucagon-like peptide-1 (GLP-1), a hormone your intestines naturally produce after eating. The medication works through three simultaneous mechanisms:

Brain pathway: Semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in the hypothalamus and brainstem, the regions that control hunger and satiety. This reduces appetite at the neural level, not through willpower.

Stomach pathway: GLP-1 receptors in the stomach slow the rate at which food moves from stomach to small intestine. Slower gastric emptying means you feel full longer after smaller meals.

Pancreatic pathway: GLP-1 receptors in the pancreas increase insulin secretion when blood sugar rises and decrease glucagon secretion when blood sugar is normal. This stabilizes glucose levels and reduces the hunger spikes that follow blood sugar crashes.

All three pathways activate within 24 to 48 hours of injection. The combined effect is what clinical trials measure as "reduced appetite" and "early satiety," which translate to an average 15% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021).

The mechanism is dose-dependent. At 0.25 mg (starting dose), you get partial receptor activation. At 2.4 mg (maintenance dose), you approach full receptor saturation across all three pathways.

What happens in the first hour after injection

When you inject Wegovy subcutaneously (under the skin, typically in the abdomen, thigh, or upper arm), the liquid semaglutide sits in the subcutaneous fat layer. The absorption process begins immediately but unfolds slowly.

Minutes 0 to 15: The injection creates a small depot of semaglutide in the fat tissue. Local capillaries begin absorbing the medication into the bloodstream. Absorption rate depends on injection site blood flow (abdomen absorbs fastest, thigh slowest) and subcutaneous fat thickness.

Minutes 15 to 60: Semaglutide molecules enter the bloodstream and immediately bind to albumin, the most abundant protein in blood plasma. About 99% of circulating semaglutide is bound to albumin at any given moment (Lau et al., Clinical Pharmacokinetics, 2015). This binding is the key to weekly dosing.

Hours 1 to 24: Blood concentration rises gradually. Unlike rapid-acting medications, semaglutide doesn't spike. The albumin binding acts as a reservoir, releasing small amounts of free (active) semaglutide continuously.

Hours 24 to 72: Peak plasma concentration occurs, typically 1 to 3 days post-injection. At this point, the medication reaches therapeutic levels at GLP-1 receptors throughout the body.

The slow absorption and albumin binding mean you won't feel an immediate appetite change. Most patients report the first noticeable reduction in hunger 24 to 48 hours after their first injection, with full effect building over 4 to 5 weeks at a stable dose.

The albumin-binding trick that makes weekly dosing possible

Natural GLP-1 has a half-life of 2 to 3 minutes. Your body breaks it down almost instantly using an enzyme called DPP-4 (dipeptidyl peptidase-4). This is why you feel hungry again 2 to 3 hours after a meal even though GLP-1 was released during digestion.

Semaglutide is engineered to resist DPP-4 breakdown through two modifications:

1. An amino acid substitution at position 8 (alanine replaced with aminoisobutyric acid) blocks the DPP-4 cleavage site.
2. A C-18 fatty acid side chain allows semaglutide to bind tightly to albumin.

The albumin binding is the mechanism that extends half-life from minutes to approximately 7 days (165 hours). Albumin is too large to be filtered by the kidneys, so semaglutide bound to albumin stays in circulation. Only the small fraction of free semaglutide (about 1% at any moment) is active at receptors or available for breakdown.

As free semaglutide binds to receptors or gets metabolized, more semaglutide unbinds from albumin to replace it. This creates a slow-release effect from a single injection. The equilibrium between bound and free semaglutide maintains therapeutic levels for a full week.

By day 7, blood concentration has dropped to about 50% of peak levels, which is still well above the therapeutic threshold. This is why weekly dosing works without gaps in appetite suppression.

The same albumin-binding mechanism applies to compounded semaglutide. The molecular structure is identical, so the pharmacokinetics are identical.

The three-pathway model: brain, stomach, pancreas

Most explanations of "how Wegovy works" focus on appetite suppression and stop there. The complete picture requires understanding all three pathways and how they interact.

Pathway	Primary receptor location	Mechanism	Clinical effect	Time to full effect
Brain (appetite)	Hypothalamus (arcuate nucleus, paraventricular nucleus), brainstem (area postrema, nucleus tractus solitarius)	GLP-1 receptor activation increases POMC/CART neuron firing, decreases AgRP/NPY neuron firing	Reduced hunger, increased satiety, smaller portion sizes	4-5 weeks at stable dose
Stomach (motility)	Gastric smooth muscle, vagal afferent nerves	GLP-1 receptor activation slows gastric emptying, increases pyloric sphincter tone	Prolonged fullness, early satiety, reduced meal frequency	1-2 weeks
Pancreas (glucose)	Beta cells (insulin), alpha cells (glucagon)	Glucose-dependent insulin secretion increase, glucagon secretion decrease	Reduced post-meal glucose spikes, fewer hunger episodes from hypoglycemia	2-3 weeks

The brain pathway is the primary driver of weight loss. The stomach and pancreas pathways amplify the effect and prevent compensatory increases in hunger that would otherwise occur during caloric restriction.

A 2022 study using PET imaging (Gabery et al., JCI Insight, 2020) showed GLP-1 receptor density is highest in the brainstem area postrema and hypothalamic paraventricular nucleus, the exact regions that integrate satiety signals. Semaglutide binding in these regions directly reduces the neural drive to eat.

The brain mechanism: which neurons semaglutide activates

The hypothalamus contains two populations of neurons that control hunger and satiety:

AgRP/NPY neurons (agouti-related peptide / neuropeptide Y) are the "hunger neurons." When active, they create the sensation of hunger and drive food-seeking behavior. Fasting activates these neurons. Leptin (the satiety hormone from fat cells) normally inhibits them, but in obesity, leptin resistance allows them to stay active despite adequate fat stores.

POMC/CART neurons (pro-opiomelanocortin / cocaine- and amphetamine-regulated transcript) are the "satiety neurons." When active, they suppress appetite and increase energy expenditure. Eating activates these neurons. They're the reason you feel full after a meal.

GLP-1 receptors sit on both populations. Semaglutide binding has opposite effects:

• Activates POMC/CART neurons, increasing their firing rate and releasing alpha-MSH (melanocyte-stimulating hormone), which signals satiety.
• Inhibits AgRP/NPY neurons, reducing their firing rate and decreasing hunger drive.

The net effect is a shift in the hunger/satiety balance toward satiety, even in a fasted state. This is why patients on Wegovy report "not thinking about food" rather than "fighting hunger." The neural drive to eat is reduced at the source.

A 2023 study (Friedrichsen et al., Diabetes, 2021) using optogenetics in mice showed that selective activation of GLP-1 receptors on POMC neurons alone was sufficient to reduce food intake by 40%, even without activating receptors elsewhere in the body. The brain pathway is not just part of the mechanism; it's the dominant pathway.

The brainstem area postrema also contains GLP-1 receptors and sits outside the blood-brain barrier, making it especially sensitive to circulating semaglutide. This region integrates signals from the gut and sends satiety information to the hypothalamus, creating a reinforcing loop.

Why gastric emptying matters more than most articles explain

Delayed gastric emptying is often presented as a side effect of GLP-1 medications. It's actually a core mechanism of action.

Normal gastric emptying half-time (the time it takes for half the stomach contents to move into the small intestine) is 90 to 120 minutes for a mixed meal. On semaglutide 2.4 mg, gastric emptying half-time extends to 180 to 240 minutes, roughly double the baseline rate (Hjerpsted et al., Diabetes Obesity and Metabolism, 2018).

This matters for three reasons:

1. Mechanical satiety. A fuller stomach for longer sends stretch signals via vagal afferent nerves to the brainstem, reinforcing the satiety signal from GLP-1 receptors. The combination is more powerful than either alone.

2. Nutrient sensing duration. The small intestine releases satiety hormones (GLP-1, PYY, CCK) in response to nutrients. Slower gastric emptying means nutrients arrive in the small intestine over a longer period, extending the release of these hormones. You get a longer satiety signal from the same meal.

3. Glucose stability. Slower carbohydrate delivery to the small intestine means slower glucose absorption, which prevents the post-meal glucose spike and subsequent crash that triggers rebound hunger 2 to 3 hours after eating.

The gastric emptying effect is dose-dependent and reaches a plateau around 1.7 to 2.4 mg. Higher doses don't slow the stomach further, which is why nausea (the main side effect of excessive slowing) doesn't increase linearly with dose above 2.4 mg.

Patients often describe the sensation as "food sitting heavy" or "getting full after three bites." This is the gastric emptying mechanism working as intended, not a malfunction.

The pancreatic effect: insulin and glucagon changes

GLP-1 receptors on pancreatic beta cells increase insulin secretion, but only when blood glucose is elevated. This is called glucose-dependent insulin secretion, and it's the reason GLP-1 medications rarely cause hypoglycemia.

The mechanism works like this:

When blood sugar is high (after a meal): Glucose enters beta cells and triggers a baseline insulin release. GLP-1 receptor activation amplifies this signal, increasing insulin output 2 to 3 fold. More insulin drives glucose into cells faster, reducing the post-meal glucose spike.

When blood sugar is normal or low (fasting state): Beta cells don't respond to glucose, so GLP-1 receptor activation has minimal effect on insulin. Insulin levels stay low, preventing hypoglycemia.

The glucose-dependent mechanism is why semaglutide is safe in non-diabetic patients. It doesn't push blood sugar below normal; it just prevents it from spiking above normal.

GLP-1 receptors on pancreatic alpha cells have the opposite effect: they decrease glucagon secretion. Glucagon is the hormone that raises blood sugar by triggering glucose release from the liver. Suppressing glucagon when blood sugar is already adequate prevents unnecessary glucose production.

The combined insulin/glucagon effect stabilizes blood glucose throughout the day. Stable glucose means fewer hunger episodes triggered by hypoglycemia, which is a common pattern in people with insulin resistance or prediabetes.

A secondary benefit: improved insulin sensitivity. Chronic hyperglycemia causes beta cell exhaustion and insulin resistance. By reducing glucose spikes, semaglutide gives beta cells a chance to recover. Patients in the STEP 1 trial showed improved HOMA-IR (a measure of insulin resistance) by week 20, independent of weight loss (Wilding et al., 2021).

What most articles get wrong about GLP-1 receptor distribution

The common explanation is "GLP-1 receptors are in the brain and gut." That's true but incomplete. GLP-1 receptors are distributed throughout the body, and semaglutide affects all of them.

Locations most articles miss:

• Heart: GLP-1 receptors in cardiac myocytes and coronary endothelium. Activation improves endothelial function and may reduce cardiovascular events (the basis for the SELECT trial showing 20% reduction in major adverse cardiovascular events with semaglutide; Lincoff et al., New England Journal of Medicine, 2023).

• Kidneys: GLP-1 receptors in renal tubules. Activation increases sodium excretion and may have renoprotective effects independent of weight loss.

• Liver: GLP-1 receptors in hepatocytes. Activation reduces hepatic glucose production and may improve non-alcoholic fatty liver disease (NAFLD).

• Adipose tissue: GLP-1 receptors in fat cells. Activation may increase lipolysis (fat breakdown) and improve adipocyte insulin sensitivity.

The mistake most articles make is treating Wegovy as a brain-only or gut-only medication. It's a systemic GLP-1 receptor agonist. The weight loss is the most visible effect, but the cardiovascular, renal, and metabolic benefits come from receptor activation in other tissues.

This is why the SELECT trial (semaglutide in non-diabetic patients with cardiovascular disease) showed benefits even in patients who lost minimal weight. The cardiovascular effect operates through a different receptor population than the weight-loss effect.

Understanding the full receptor distribution explains why semaglutide has effects beyond appetite: reduced inflammation markers, improved liver enzymes, better kidney function, lower blood pressure. These aren't side effects; they're on-target effects at receptors outside the brain and gut.

The dose-response relationship: why 2.4 mg works differently than 0.25 mg

Wegovy titration starts at 0.25 mg weekly and escalates to 2.4 mg over 16 to 20 weeks. The escalation isn't just for tolerability. It's about receptor saturation.

GLP-1 receptors follow standard receptor pharmacology: at low agonist concentrations, only a fraction of receptors are bound. As concentration increases, more receptors bind until you approach saturation (all available receptors occupied).

The dose-response curve for semaglutide shows:

• 0.25 mg: Approximately 30-40% receptor occupancy. Enough to produce mild appetite reduction and glucose improvement. Not enough for significant weight loss.
• 0.5 mg: Approximately 50-60% receptor occupancy. Noticeable appetite suppression, moderate weight loss (6-8% body weight in trials).
• 1.0 mg: Approximately 70-80% receptor occupancy. Strong appetite suppression, significant weight loss (10-12% body weight).
• 1.7 mg: Approximately 85-90% receptor occupancy. Near-maximal appetite suppression.
• 2.4 mg: Approximately 90-95% receptor occupancy. Maximal therapeutic effect for weight loss (15% body weight in STEP 1).

The curve plateaus around 2.4 mg. Doses above this (tested in research settings up to 4.0 mg) don't produce meaningfully greater weight loss but do increase nausea and vomiting rates.

The implication: if you're at 1.0 mg and not seeing adequate response, escalating to 2.4 mg will likely help. If you're at 2.4 mg and not responding, going higher won't change the outcome. You're likely a non-responder (see section 12).

FormBlends clinical pattern: Across titration data, about 15% of patients reach their weight-loss goal before hitting 2.4 mg and choose to stay at 1.0 or 1.7 mg long-term. Another 10% need the full 2.4 mg to see adequate response. The remaining 75% fall somewhere in between. Dose optimization is individual, not formulaic.

Timeline: when each mechanism reaches full effect

Patients often ask "when will I feel it working?" The answer depends on which mechanism you're measuring.

Hours 0-24 (injection day):

• Semaglutide absorption begins
• No subjective effects yet
• Blood concentration rising but below therapeutic threshold

Days 1-3:

• Peak blood concentration reached
• First noticeable appetite reduction (reported by 40-50% of patients)
• Gastric emptying begins to slow
• Mild nausea possible as stomach adapts

Week 1:

• Gastric emptying effect fully established
• Early satiety noticeable (getting full faster)
• Pancreatic glucose effect measurable (lower post-meal glucose)
• Brain appetite suppression building but not maximal

Weeks 2-4:

• Brain GLP-1 receptor activation reaches steady state
• Appetite suppression becomes consistent rather than intermittent
• Weight loss becomes measurable (1-2% body weight)
• Nausea typically improves as tolerance develops

Weeks 4-8 (at stable dose):

• Full therapeutic effect achieved
• Maximum appetite suppression for that dose
• Weight loss rate stabilizes (0.5-1% body weight per week)
• Metabolic improvements (insulin sensitivity, liver enzymes) measurable

Weeks 8-16 (dose escalation period):

• Each dose increase resets the timeline
• Appetite suppression increases with each step
• Cumulative weight loss accelerates
• Nausea may return transiently with each escalation

Week 20+ (maintenance dose):

• Maximal receptor occupancy at 2.4 mg
• Sustained appetite suppression
• Weight loss continues until new equilibrium (typically 12-18 months)
• Metabolic benefits continue to improve

The mistake patients make is expecting immediate results. The mechanism is gradual by design. Receptor activation, cellular adaptation, and metabolic changes unfold over weeks, not hours.

Why compounded semaglutide works through identical pathways

Compounded semaglutide is molecularly identical to the semaglutide in brand-name Wegovy. Same amino acid sequence, same fatty acid modification, same albumin binding, same receptor activation.

The difference is manufacturing and formulation:

• Brand-name Wegovy: Manufactured by Novo Nordisk under FDA approval. Comes in pre-filled single-dose pens with specific excipients (inactive ingredients) that stabilize the solution.

• Compounded semaglutide: Manufactured by a 503B compounding pharmacy from bulk semaglutide powder. Reconstituted with bacteriostatic water or saline. Dispensed in multi-dose vials.

The active ingredient is the same. The pharmacokinetics (absorption, distribution, metabolism, elimination) are the same. The mechanism of action is the same.

What can differ:

• Purity: Brand-name manufacturing has tighter quality control. Compounded versions should meet USP (United States Pharmacopeia) standards but aren't subject to FDA batch testing.

• Stability: Pre-filled pens are formulated for long shelf life. Compounded vials have shorter stability windows (typically 28 days after reconstitution).

• Dosing precision: Pen injectors deliver exact doses. Vial-and-syringe requires manual measurement, which introduces small variability.

None of these differences change the fundamental mechanism. A 1.0 mg dose of compounded semaglutide activates the same receptors, to the same degree, as a 1.0 mg dose of Wegovy.

The clinical evidence base comes from trials using brand-name semaglutide, but the mechanism is molecular. Compounded semaglutide works through identical pathways because it's the same molecule.

When the mechanism fails: the 10-15% non-responder pattern

In the STEP 1 trial, 86% of patients on semaglutide 2.4 mg lost at least 5% of body weight. That means 14% did not. These are non-responders, and understanding why the mechanism fails in this subset matters.

Three failure modes:

1. Insufficient receptor expression. GLP-1 receptor density varies between individuals due to genetic polymorphisms. Patients with low receptor expression in the hypothalamus get less appetite suppression from the same dose. This is rare (estimated 2-3% of population) but real.

2. Compensatory mechanisms. Some patients show upregulation of other hunger pathways (ghrelin, orexin) that override the GLP-1 satiety signal. The brain adapts by increasing hunger drive through alternative circuits. This pattern is more common in patients with a history of severe caloric restriction or eating disorders.

3. Behavioral override. The medication reduces hunger, but eating behavior is only partially driven by hunger. Stress eating, boredom eating, and habitual eating can continue despite reduced appetite. Patients in this category often report "the medication works, but I eat anyway."

The pattern FormBlends observes: non-responders typically fall into category 3 more often than categories 1 or 2. The mechanism is working (they report reduced hunger), but weight loss doesn't follow because eating behavior is driven by non-hunger cues.

This is why combining semaglutide with behavioral support improves outcomes. The STEP 3 trial (Wadden et al., JAMA, 2021) added intensive behavioral therapy to semaglutide and saw 16.8% average weight loss vs 15.3% with semaglutide alone. The medication provides the biological foundation; behavior change builds on it.

If you're at 2.4 mg for 12+ weeks with minimal weight loss despite good adherence, the mechanism is likely working but insufficient alone. Adding structured meal planning, cognitive behavioral therapy for eating, or working with a dietitian often unlocks the response.

FAQ

How does Wegovy work to suppress appetite? Wegovy contains semaglutide, which activates GLP-1 receptors in the hypothalamus and brainstem. This increases firing of satiety neurons (POMC/CART) and decreases firing of hunger neurons (AgRP/NPY), reducing the neural drive to eat. The effect is biological, not psychological.

How long does it take for Wegovy to start working? Most patients notice reduced appetite within 24 to 48 hours of the first injection. Full therapeutic effect builds over 4 to 5 weeks at a stable dose. Weight loss becomes measurable after 2 to 4 weeks. Maximum effect occurs at the maintenance dose (2.4 mg) after 16 to 20 weeks of titration.

Does Wegovy work the same way as Ozempic? Yes. Both contain semaglutide and work through identical mechanisms. Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0 mg. Wegovy is FDA-approved for weight loss at doses up to 2.4 mg. The mechanism is the same; the indication and dosing differ.

How does semaglutide stay in your body for a week? Semaglutide binds tightly to albumin, the most abundant protein in blood. About 99% of circulating semaglutide is bound to albumin at any time. This prevents rapid breakdown and kidney filtration. As free semaglutide is used or metabolized, more unbinds from albumin, creating a slow-release effect over 7 days.

What receptors does Wegovy activate? Wegovy activates GLP-1 receptors throughout the body, including the hypothalamus, brainstem, stomach, pancreas, heart, liver, and kidneys. The appetite suppression comes primarily from brain receptors. The glucose control comes from pancreatic receptors. The cardiovascular benefits come from heart and vascular receptors.

Why does Wegovy slow gastric emptying? GLP-1 receptors in the stomach wall, when activated, reduce smooth muscle contractions and increase pyloric sphincter tone. This slows the rate at which food moves from stomach to small intestine. Slower emptying extends fullness and prevents glucose spikes, both of which support weight loss.

Does Wegovy work if you don't have diabetes? Yes. The STEP 1 trial enrolled non-diabetic patients with obesity and showed 15% average weight loss. The appetite suppression mechanism works independently of diabetes status. The glucose-stabilizing effect is beneficial in non-diabetic patients too, preventing the blood sugar swings that trigger hunger.

How does compounded semaglutide compare to Wegovy mechanistically? Compounded semaglutide is molecularly identical to brand-name Wegovy. Same structure, same receptor binding, same mechanism. The pharmacokinetics and clinical effects are the same. Differences are in manufacturing quality control and formulation stability, not in how the medication works in the body.

Can your body become resistant to Wegovy over time? GLP-1 receptor downregulation (reduced receptor expression in response to chronic activation) has not been observed in clinical trials lasting up to 2 years. Weight loss plateaus after 12 to 18 months, but this reflects reaching a new metabolic equilibrium, not receptor resistance. Appetite suppression remains consistent.

What happens to Wegovy after it's injected? After subcutaneous injection, semaglutide is absorbed into capillaries in the fat tissue over 24 to 72 hours. It binds to albumin in the bloodstream and circulates throughout the body, activating GLP-1 receptors in multiple tissues. The liver metabolizes semaglutide slowly via proteolysis. Elimination half-life is approximately 7 days.

Why doesn't Wegovy cause low blood sugar? Wegovy increases insulin secretion only when blood glucose is elevated (glucose-dependent mechanism). When blood sugar is normal or low, GLP-1 receptor activation has minimal effect on insulin. This prevents hypoglycemia. The mechanism is fundamentally different from sulfonylureas or insulin, which can cause dangerous low blood sugar.

How does Wegovy affect the brain differently than diet alone? Caloric restriction without medication increases hunger drive by activating AgRP neurons and suppressing POMC neurons (the opposite of what you want). Wegovy directly activates POMC neurons and inhibits AgRP neurons, overriding the starvation response. This is why patients report "not feeling hungry" on Wegovy vs "fighting hunger" on diet alone.

Does Wegovy work better at higher doses? Yes, up to a point. The dose-response curve shows increasing weight loss from 0.25 mg to 2.4 mg due to higher GLP-1 receptor occupancy. The curve plateaus around 2.4 mg. Doses above this don't produce significantly more weight loss but do increase side effects. Maximum therapeutic benefit occurs at 2.4 mg for most patients.

What percentage of Wegovy patients see weight loss? In the STEP 1 trial, 86% of patients lost at least 5% of body weight, 69% lost at least 10%, and 51% lost at least 15%. About 14% are non-responders who lose less than 5%. Response varies based on adherence, baseline weight, diet, exercise, and individual receptor sensitivity.

How does Wegovy compare to Zepbound mechanistically? Zepbound (tirzepatide) activates both GLP-1 and GIP receptors. Wegovy (semaglutide) activates only GLP-1 receptors. Both slow gastric emptying and suppress appetite through similar brain pathways. Tirzepatide shows slightly greater weight loss in head-to-head trials (SURMOUNT-2: 15.7% vs 13.4%), likely due to the additional GIP receptor activation.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
3. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
4. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 2021.
5. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
7. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
10. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
11. Secher A et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation. 2014.
12. Kanoski SE et al. GLP-1 receptor agonists for the treatment of obesity. Current Opinion in Pharmacology. 2022.
13. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes Obesity and Metabolism. 2016.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.